@article {2429, title = {Effect of Cacao Bean Extract as a Paracetamol Adjuvant on Pain Scale and Tumor Necrosis Factor-Alpha in Neuropathic Pain: An Animal Model Study}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {December 2024}, pages = {1336-1341}, type = {Research Article}, chapter = {1336}, abstract = {

Introduction: One treatment for neuropathic pain is paracetamol. Meanwhile, cacao bean extract is a traditional remedy developed for pain management. Objective: Analyzing effect of combining cacao bean extract and paracetamol on pain scale and tumor necrosis factor-alpha (TNF-α) in neuropathic pain. Methods: Subjects were randomized post-test only control group design from 28 mice (Mus musculus) to 4 groups: G0 (control), G1 (paracetamol only), G2 (cacao + paracetamol), and G3 (cacao + {\textonehalf} doses paracetamol). The subject assessed pain scale using von Frey test and TNF-α. The statistical analysis includes paired t-tests, Wilcoxon, one-way ANOVA, Kruskal Wallis, and Pearson correlation tests with p \<0.05. Results: The combination of cacao bean extract and paracetamol resulted in a pain scale of 2.57 {\textpm} 1.10 gf, with significant differences observed among the four groups (p \<0.001). Significant differences in pain scale scores were found in four groups (p \<0.001), including G0 (p = 0.006), G1 (p \<0.001), G2 (p \<0.001), and G3 (p \<0.001). After treatment, the average TNF-α levels was 86.96 {\textpm} 23.73 ng/mL, with significant differences observed among the four groups (p \<0.001). There was a strong correlation between the pain scale and TNF-α levels (p \<0.001). Conclusion: In an animal model of neuropathic pain, using cacao bean extract as a paracetamol adjuvant significantly reduces pain scale (as measured by the von Frey test) and TNF-α levels.

}, keywords = {Cacao, Neuropathic pain, pain scale, Paracetamol, TNF-α}, doi = {10.5530/pj.2024.16.215}, author = {Faiz Muhammad Ammar and Christrijogo Sumartono Waloejo and Herdiani Sulistyo Putri and Kohar Hari Santoso and Prananda Surya Airlangga and Budi Utomo} } @article {2396, title = {Effective Dose of Cocoa as a Preemptive Analgesic and Anti- Inflammatory Agent Assessed through Pain Scale and Tumor Necrosis Factor Alpha (TNF-α) in an Acute Pain Animal Model}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {October 2024}, pages = {1134-1137}, type = {Research Article}, chapter = {1134}, abstract = {

Background: Pain is a significant issue for 40-50\% of hospital patients, with 10-50\% of acute pain cases potentially progressing to chronic pain. Pain-associated inflammation often involves the release of mediators, including Tumor Necrosis Factor Alpha (TNF-α). Cocoa beans contain polyphenols, catechins, anthocyanidins, and proanthocyanidins, compounds believed to possess analgesic properties. This study aims to assess cocoa{\textquoteright}s potential as an oral preemptive analgesic agent in an acute pain mouse model, with an emphasis on its impact on inflammation through TNF-α levels. Methods: This true experimental study involved 24 male white mice split into four groups: a control group (K0) receiving a placebo, a treatment group receiving 15 mg/kg BW oral paracetamol (Kpct), a treatment group receiving 0.5 mg/g BW cocoa (K1), and a treatment group receiving 1 mg/g BW cocoa (K2). Pain response was measured using TNF-α levels and the von Frey test. The Kruskal-Wallis test and One-Way ANOVA were employed for statistical analysis. Results: Cocoa at doses of 0.5 mg/g BW and 1 mg/g BW substantially reduced TNF-α levels (75.82 {\textpm} 7.77 and 70.79 {\textpm} 11.50, respectively) compared to the control and paracetamol groups (98.22 {\textpm} 14.74 and 92.81 {\textpm} 2.64). On the first day, compared to the control group{\textquoteright}s 1.82 {\textpm} 0.78 von Frey values, the cocoa-treated groups{\textquoteright} values (6.20 {\textpm} 2.72 and 7.63 {\textpm} 4.11) were notably higher. There were no notable variations in von Frey values across the groups on the second day. However, a correlation was found between von Frey values on the first and second days. Conclusion: Cocoa can potentially serve as an effective preemptive analgesic agent, reducing pain and inflammation primarily by reducing TNF-α levels. These results provide validity to the use of cocoa as an alternative therapy in acute pain management.

}, keywords = {Cocoa, Pain, Pain Degree Analgesia, TNF-α}, doi = {10.5530/pj.2024.16.185}, author = {Herry Cahya Fathani and Herdiani Sulistyo Putri and Prananda Surya Airlangga and Christrijogo Sumartono Waloejo and Ira Sari Yudaniayanti and Pudji Lestari} } @article {2408, title = {Transient Receptor Potential Vanilloid 1 in Acute Pain: A Literature Review}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {October 2024}, pages = {1196-1201}, type = {Review Article}, chapter = {1196}, abstract = {

Transient Receptor Potential Vanilloid 1 (TRPV1) is a protein that functions as a non-selective channel receptor that is widely expressed in skin tissue, including keratinocytes, peripheral sensory nerve fibers, and immune cells. Several structural features of TRPV1 are involved in heat-induced activation, where stimulation of TRPV1 elicits a burning sensation, reflecting the receptor{\textquoteright}s important role in pain. A TRPV1- mediated signalling pathway that functions as an endogenous pain resolution mechanism by inducing nuclear translocation of β-arrestin2 to minimize desensitization of μ-opioid receptors (MOR). TRPV1 agonists can reduce pain primarily by interfering with pain nerve conduction. Several TRPV1 antagonist drug candidates have failed in clinical trials because by interfering with the detection of the above-mentioned stimuli, they triggered serious side effects such as hyperthermia and painful impaired heat detection. In the case of agonists, systemic administration causes more severe side effects such as respiratory damage. Therefore, only topical preparations with limited effectiveness have been developed. The TRPV1 agonist capsaicin is currently the only one approved for the treatment of muscle, bone, neuropathic pain and migraine, and is only available as a low-concentration cream or as a transdermal patch.

}, keywords = {Agonis TRPV1, Capsaicin, Pain, transient receptor potential vanilloid 1}, doi = {10.5530/pj.2024.16.196}, author = {Dian Retno Mumpuni and Herdiani Sulistyo Putri and Prananda Surya Airlangga and Christrijogo Sumartono Waloejo} }